论文部分内容阅读
目的为了探索进展期胃肠肿瘤的有效治疗方法,对持续热灌注腹腔化疗(Hyperthermicintraperito-nealchemoperfusion,HIPC)、腹腔化疗和单纯静脉化疗进行临床研究和初步疗效评价。方法回顾性分析了1999年9月~2003年10月住院进展期胃肠肿瘤患者53例,分别接受HIPC+静脉化疗(HIPC+IVC,14例)、单纯静脉化疗(SIVC,21例)和常规腹腔化疗+静脉化疗(IPC+IVC,18例)3种治疗方法,治疗2个周期以上,分析其疗效差异。结果与IPC+IVC组或SIVC组相比,HIPC+IVC组病人缓解率、总体疗效有明显差异(P<0.05),且在治疗转移性腹水方面有明显的优势(P<0.05),但对肝转移灶缩小方面的疗效优势不能肯定(P>0.05)。引起全身副作用比SIVC组小,对机体的免疫打击小。患者生活质量改善明显,临床受益率高。结论对于进展期胃肠肿瘤患者,HIPC+IVC疗效好,副作用小,患者住院天数少,平均住院费低,收益/投入高。
Objective To explore the effective treatment of advanced gastrointestinal neoplasms and evaluate the clinical efficacy and clinical efficacy of continuous hyperthermic intraperitoneal chemotherapy (HIPC), intraperitoneal chemotherapy and simple intravenous chemotherapy. Methods A retrospective analysis of 53 patients with advanced gastrointestinal cancer admitted to our hospital from September 1999 to October 2003 were performed HIPC plus IVC (n = 14), intravenous chemotherapy (n = 21) and conventional abdominal cavity Chemotherapy + intravenous chemotherapy (IPC + IVC, 18 cases) three kinds of treatment methods, more than two cycles of treatment, analysis of the differences in their efficacy. Results Compared with IPC + IVC group or SIVC group, the response rate and overall curative effect of HIPC + IVC group were significantly different (P <0.05), and had obvious advantages in the treatment of metastatic ascites (P <0.05) The efficacy advantage of reduced liver metastases can not be affirmed (P> 0.05). Cause systemic side effects than the SIVC group small immune hit on the body. Significant improvement in the quality of life of patients with high clinical benefit. Conclusion For patients with advanced gastrointestinal cancer, HIPC + IVC has good curative effect, small side effects, less days of hospitalization, lower average hospitalization cost, and higher income / investment.